赛诺菲为法兰克福胰岛素API新厂举行破土仪式，系2024年已公布、2032年才投产的长期产能项目

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany
Paris and Frankfurt, October 19, 2
026.
Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The new facility will bring a new generation of insulin production to one of Sanofi’s largest integrated research and manufacturing sites, strengthening Sanofi’s long-term ability to provide a reliable supply of insulin to millions of people living with diabetes around the world.
Prime Minister of the State of Hesse Boris Rhein and Mayor of Frankfurt Mike Josef joined Belén Garijo, Chief Executive Officer of Sanofi, Brendan O’Callaghan, Sanofi Executive Vice President, Manufacturing & Supply and Chairman of the Supervisory Board of Sanofi in Germany, and Madeleine Roach, Country President of Sanofi in Germany, at today’s groundbreaking ceremony.
“Millions of people around the world rely on insulin every day, and our commitment to them is for the long term. With this new facility, we are investing in the next generation of insulin manufacturing in Europe, building on more than a century of expertise and a strong industrial footprint in Frankfurt. Maintaining the right conditions for investment and innovation will be essential to Europe’s future competitiveness,” said
Belén Garijo,
Chief Executive Officer, Sanofi.
Investing in the next generation of insulin manufacturing
The new facility will be built on a 36,000-square-meter footprint at the Sanofi BioCampus in Frankfurt, equivalent to approximately five football fields. Designed to meet the highest standards of quality and automation, it will leverage advanced digital technologies and artificial intelligence across manufacturing and quality processes.
Full production of insulin active pharmaceutical ingredient is planned for 2032, once the facility is fully licensed. Building on more than a century of manufacturing expertise in Frankfurt, the facility will combine advanced manufacturing technologies, automation and digital capabilities. Once operational, it will be among the largest and most advanced insulin manufacturing facilities in Europe and an important part of Sanofi’s global insulin supply network.
The Frankfurt BioCampus covers the entire insulin manufacturing value chain, from active pharmaceutical ingredient production to filling, device assembly, and packaging, with around 4,000 employees dedicated to insulin and approximately 20 insulin products supplied from the site.
A long-term commitment to people living with diabetes
More than 500 million people worldwide live with diabetes, and millions rely on insulin every day. With the number of people living with diabetes expected to rise to more than 800 million by 2050, and as the global insulin supply landscape evolves, reliable long-term insulin supply will remain essential.
Sanofi currently supplies insulin to approximately 15 million people in more than 100 countries each year. The new Frankfurt facility reflects Sanofi’s long-term commitment to people who rely on insulin every day and will help ensure its global manufacturing network is equipped to serve patients for decades to come.
Sanofi announced its plans for the new Frankfurt facility in August 2024. In September 2026, the European Commission approved public support from the German Federal Government, the State of Hesse and the City of Frankfurt under the European Union’s state aid framework.
Rendering
of the new insulin manufacturing facility at Sanofi
Bio
C
ampus
Frankfurt.
__________________________________________________________________________
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sanofi
Global
Media Relations
Sandrine Guendoul
| +33 6 25 09 14 25 |
sandrine.guendoul@sanofi.com
Evan Berland
| +1 215 432 0234 |
evan.berland@sanofi.com
Léo Le
Bourhis
| +33 6 75 06 43 81 |
leo.lebourhis@sanofi.com
Victor Rouault
| +1 617 356 4751 |
victor.rouault@sanofi.com
Timothy Gilbert
| +1 516 521 2929 |
timothy.gilbert@sanofi.com
Léa Ubaldi
| +33 6 30 19 66 46 |
lea.ubaldi@sanofi.com
Laura Romby
| +33 6 74 16 74 29 |
laura.romby@sanofi.com
Ekaterina Pesheva
| +1 410 926 6780 |
ekaterina.pesheva@sanofi.com
Sanofi Germany Media Relations
Stefan Dietrich
| +49 69 305 30165 |
presse@sanofi.com
Miriam Liebelt-Henn
| +49 69 305 5085 |
presse@sanofi.com
Ralph Hug
| +49 69 305 15907 |
presse@sanofi.com
Sanofi Investor Relations
Thomas Kudsk Larsen
| +44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé
Kaisserian
| +33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Keita Browne
| +1 781 249 1766 |
keita.browne@sanofi.com
Nathalie Pham
| +33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Nina Goworek
| +1 908 569 7086 |
nina.goworek@sanofi.com
Thibaud Châtelet
| +33 6 80 80 89 90 |
thibaud.chatelet@sanofi.com
Yun Li
| +33 6 84 00 90 72 |
yun.li3@sanofi.com
Sanofi
Forwar
d-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product.  Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements.
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.
Attachment
Press Release